Hematologic cancer, also known as blood cancer or hematopoietic cancer, is a type of cancer that affects the blood, bone marrow, and lymphatic system. This type of cancer occurs when there is an abnormal growth of blood cells in the body, which can lead to the formation of tumors and affect the body’s ability to fight infections.
Hematologic cancers can be broadly categorized into three types: leukemia, lymphoma, and myeloma. The diagnosis and treatment of hematologic cancer depend on the specific type of cancer, stage, and other individual factors. Early diagnosis and treatment are important to improve the prognosis and overall survival of patients with hematologic cancer.
Epidemiology
Incidence: Hematologic malignancies have an annual incidence of approximately 75,000 new cases in the United States.
Mortality: Approximately 50,000 people die from hematologic malignancies each year in the United States.
Age: The incidence of hematologic malignancies increases with age. For example, the median age at diagnosis for multiple myeloma is 69 years, while the median age at diagnosis for acute lymphoblastic leukemia is 15 years.
Gender: Hematologic malignancies affect men and women equally, with the exception of some subtypes, such as Hodgkin lymphoma, which has a slightly higher incidence in males.
Race and Ethnicity: Some types of hematologic malignancies, such as multiple myeloma and Hodgkin lymphoma, have a higher incidence among African Americans and Hispanics.
Anatomy
Pathophysiology
The pathophysiology of hematologic cancers varies depending on the specific type of cancer and can involve mutations in the DNA, uncontrolled cell proliferation, and inhibition of apoptosis.
Mutations in DNA: Hematologic cancers often occur because of genetic mutations in the DNA of blood or bone marrow cells. These mutations can affect the growth and differentiation of blood cells, leading to uncontrolled proliferation and ultimately cancer development.
Uncontrolled cell proliferation: In hematologic cancers, abnormal blood cells proliferate at a rapid rate, leading to an imbalance in the ratio of normal to abnormal cells. This proliferation can lead to the formation of tumors, which can interfere with the normal functioning of the blood and lymphatic system.
Inhibition of apoptosis: Apoptosis, or programmed cell death, is a normal process that helps to remove damaged or abnormal cells from the body. In hematologic cancers, this process is often inhibited, allowing cancerous cells to survive and proliferate.
Etiology
Genetic mutations: Hematologic cancers are often associated with genetic mutations that occur spontaneously or are inherited. Certain genetic mutations, such as the BCR-ABL gene fusion, are strongly associated with the development of chronic myeloid leukemia (CML).
Environmental factors: Exposure to certain toxins and chemicals, such as benzene and pesticides, has been linked to the development of hematologic cancers.
Viral infections: Certain viral infections, such as Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus type 1 (HTLV-1), have been associated with an increased risk of hematologic cancers.
Immune system disorders: Hematologic cancers may develop in individuals with certain immune system disorders, such as autoimmune diseases and immunodeficiency disorders.
Genetics
Prognostic Factors
Type of cancer: The prognosis for hematologic cancer varies depending on the specific type of cancer. For example, acute myeloid leukemia (AML) has a generally poorer prognosis than Hodgkin’s lymphoma.
Disease stage: The stage of the cancer at diagnosis is an important factor in predicting prognosis. Hematologic cancers are often classified based on the extent of the disease, ranging from stage I (localized disease) to stage IV (widespread disease).
Molecular characteristics: The presence of certain genetic or molecular abnormalities can impact the prognosis of hematologic cancers. For example, the presence of the Philadelphia chromosome in chronic myelogenous leukemia (CML) is associated with a poorer prognosis.
Patient age and overall health: younger patients with good overall health tend to have a better prognosis than older patients or those with underlying medical conditions.
Response to treatment: Response to initial treatment is a strong predictor of long-term prognosis. Patients who respond well to initial treatment tend to have better outcomes than those who do not.
Presence of comorbidities: The presence of other medical conditions, such as heart disease or diabetes, can impact the prognosis of hematologic cancers.
Clinical History
CLINICAL HISTORY
The clinical history of hematologic cancer can vary depending on the type of cancer and its stage. Generally, patients with hematologic cancer may present with symptoms such as fatigue, weakness, weight loss, night sweats, fever, easy bruising or bleeding, frequent infections, bone pain, and swollen lymph nodes. However, some patients may not experience any symptoms at all, and the cancer may only be detected through routine blood tests or imaging studies.
It is important for individuals with a family history of hematologic cancer or other risk factors to undergo regular check-ups and screenings to detect any abnormalities early on. A thorough medical history, physical examination, and laboratory tests are necessary to confirm the diagnosis of hematologic cancer.
Physical Examination
PHYSICAL EXAMINATION
The physical examination for hematologic cancer will involve a thorough assessment of the patient’s overall health and physical condition, with a particular focus on the lymph nodes, spleen, and liver. The examination may include the following:
Lymph node: A thorough examination of the lymph nodes is essential as lymphomas often present with lymphadenopathy. The size, location, and consistency of the lymph nodes are assessed.
Abdominal examination: An enlarged spleen or liver may indicate the presence of a hematologic malignancy. The liver and spleen are palpated to assess their size, consistency, and tenderness.
Skin: The skin may show signs of involvement in some cases of hematologic malignancies such as cutaneous T-cell lymphoma or leukemia cutis. The skin is examined for any lesions, nodules, or rash.
Neurological examination: Patients with hematologic malignancies may present with neurological symptoms such as headaches, visual changes, or peripheral neuropathy. A thorough neurological examination is performed to assess the patient’s mental status, cranial nerves, motor function, and sensory function.
Bone: Patients with hematologic malignancies may present with bone pain or pathologic fractures. A thorough examination of the bones is performed to assess any tenderness or deformities.
Chest: Chest X-ray is usually performed to assess the presence of any mediastinal masses or pulmonary infiltrates.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
DIFFERENTIAL DIAGNOSIS
Other types of cancer – non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, leukemia, multiple myeloma, and other types of solid tumors.
Non-cancerous hematologic conditions – Anemia, thrombocytopenia, leukopenia, and other non-malignant hematologic disorders.
Infectious diseases – Some viral and bacterial infections, such as HIV/AIDS, hepatitis B and C, and Epstein-Barr virus infection, can cause symptoms like those of hematologic cancer.
Autoimmune diseases – Some autoimmune diseases, such as lupus, rheumatoid arthritis, and Sjogren’s syndrome, can cause similar symptoms as hematologic cancer.
Other conditions – Other medical conditions such as thyroid disorders, diabetes, and chronic liver or kidney disease can also cause symptoms like hematologic cancer.
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Chemotherapy: It is used to destroy cancer cells in the body. It is often the first-line treatment for hematologic cancers. The drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) are commonly used to treat non-Hodgkin lymphoma.
Radiation therapy: Radiation therapy is the use of high-energy radiation to kill cancer cells. This is used to treat some types of lymphoma and leukemia.
Stem cell transplant: It is a procedure in which healthy blood-forming cells are given to replace damaged or destroyed cells. High doses of chemotherapy and/or radiation are used to destroy cancer cells followed by transplanting healthy stem cells to replace the damaged ones.
Targeted therapy: It is a type of cancer treatment that uses drugs to target specific molecules involved in the growth and spread of cancer cells. Targeted therapy drugs such as imatinib, dasatinib, and nilotinib are used to treat chronic myeloid leukemia.
Immunotherapy: It is a type of cancer treatment that helps the immune system to fight against cancer cells. Immunotherapy drugs such as pembrolizumab and nivolumab are used to treat Hodgkin lymphoma and some types of leukemia.
Surgery: Surgery may be performed to remove cancer cells or tissues from the body.
Hematologic cancer, also known as blood cancer or hematopoietic cancer, is a type of cancer that affects the blood, bone marrow, and lymphatic system. This type of cancer occurs when there is an abnormal growth of blood cells in the body, which can lead to the formation of tumors and affect the body’s ability to fight infections.
Hematologic cancers can be broadly categorized into three types: leukemia, lymphoma, and myeloma. The diagnosis and treatment of hematologic cancer depend on the specific type of cancer, stage, and other individual factors. Early diagnosis and treatment are important to improve the prognosis and overall survival of patients with hematologic cancer.
Incidence: Hematologic malignancies have an annual incidence of approximately 75,000 new cases in the United States.
Mortality: Approximately 50,000 people die from hematologic malignancies each year in the United States.
Age: The incidence of hematologic malignancies increases with age. For example, the median age at diagnosis for multiple myeloma is 69 years, while the median age at diagnosis for acute lymphoblastic leukemia is 15 years.
Gender: Hematologic malignancies affect men and women equally, with the exception of some subtypes, such as Hodgkin lymphoma, which has a slightly higher incidence in males.
Race and Ethnicity: Some types of hematologic malignancies, such as multiple myeloma and Hodgkin lymphoma, have a higher incidence among African Americans and Hispanics.
The pathophysiology of hematologic cancers varies depending on the specific type of cancer and can involve mutations in the DNA, uncontrolled cell proliferation, and inhibition of apoptosis.
Mutations in DNA: Hematologic cancers often occur because of genetic mutations in the DNA of blood or bone marrow cells. These mutations can affect the growth and differentiation of blood cells, leading to uncontrolled proliferation and ultimately cancer development.
Uncontrolled cell proliferation: In hematologic cancers, abnormal blood cells proliferate at a rapid rate, leading to an imbalance in the ratio of normal to abnormal cells. This proliferation can lead to the formation of tumors, which can interfere with the normal functioning of the blood and lymphatic system.
Inhibition of apoptosis: Apoptosis, or programmed cell death, is a normal process that helps to remove damaged or abnormal cells from the body. In hematologic cancers, this process is often inhibited, allowing cancerous cells to survive and proliferate.
Genetic mutations: Hematologic cancers are often associated with genetic mutations that occur spontaneously or are inherited. Certain genetic mutations, such as the BCR-ABL gene fusion, are strongly associated with the development of chronic myeloid leukemia (CML).
Environmental factors: Exposure to certain toxins and chemicals, such as benzene and pesticides, has been linked to the development of hematologic cancers.
Viral infections: Certain viral infections, such as Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus type 1 (HTLV-1), have been associated with an increased risk of hematologic cancers.
Immune system disorders: Hematologic cancers may develop in individuals with certain immune system disorders, such as autoimmune diseases and immunodeficiency disorders.
Type of cancer: The prognosis for hematologic cancer varies depending on the specific type of cancer. For example, acute myeloid leukemia (AML) has a generally poorer prognosis than Hodgkin’s lymphoma.
Disease stage: The stage of the cancer at diagnosis is an important factor in predicting prognosis. Hematologic cancers are often classified based on the extent of the disease, ranging from stage I (localized disease) to stage IV (widespread disease).
Molecular characteristics: The presence of certain genetic or molecular abnormalities can impact the prognosis of hematologic cancers. For example, the presence of the Philadelphia chromosome in chronic myelogenous leukemia (CML) is associated with a poorer prognosis.
Patient age and overall health: younger patients with good overall health tend to have a better prognosis than older patients or those with underlying medical conditions.
Response to treatment: Response to initial treatment is a strong predictor of long-term prognosis. Patients who respond well to initial treatment tend to have better outcomes than those who do not.
Presence of comorbidities: The presence of other medical conditions, such as heart disease or diabetes, can impact the prognosis of hematologic cancers.
CLINICAL HISTORY
The clinical history of hematologic cancer can vary depending on the type of cancer and its stage. Generally, patients with hematologic cancer may present with symptoms such as fatigue, weakness, weight loss, night sweats, fever, easy bruising or bleeding, frequent infections, bone pain, and swollen lymph nodes. However, some patients may not experience any symptoms at all, and the cancer may only be detected through routine blood tests or imaging studies.
It is important for individuals with a family history of hematologic cancer or other risk factors to undergo regular check-ups and screenings to detect any abnormalities early on. A thorough medical history, physical examination, and laboratory tests are necessary to confirm the diagnosis of hematologic cancer.
PHYSICAL EXAMINATION
The physical examination for hematologic cancer will involve a thorough assessment of the patient’s overall health and physical condition, with a particular focus on the lymph nodes, spleen, and liver. The examination may include the following:
Lymph node: A thorough examination of the lymph nodes is essential as lymphomas often present with lymphadenopathy. The size, location, and consistency of the lymph nodes are assessed.
Abdominal examination: An enlarged spleen or liver may indicate the presence of a hematologic malignancy. The liver and spleen are palpated to assess their size, consistency, and tenderness.
Skin: The skin may show signs of involvement in some cases of hematologic malignancies such as cutaneous T-cell lymphoma or leukemia cutis. The skin is examined for any lesions, nodules, or rash.
Neurological examination: Patients with hematologic malignancies may present with neurological symptoms such as headaches, visual changes, or peripheral neuropathy. A thorough neurological examination is performed to assess the patient’s mental status, cranial nerves, motor function, and sensory function.
Bone: Patients with hematologic malignancies may present with bone pain or pathologic fractures. A thorough examination of the bones is performed to assess any tenderness or deformities.
Chest: Chest X-ray is usually performed to assess the presence of any mediastinal masses or pulmonary infiltrates.
DIFFERENTIAL DIAGNOSIS
Other types of cancer – non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, leukemia, multiple myeloma, and other types of solid tumors.
Non-cancerous hematologic conditions – Anemia, thrombocytopenia, leukopenia, and other non-malignant hematologic disorders.
Infectious diseases – Some viral and bacterial infections, such as HIV/AIDS, hepatitis B and C, and Epstein-Barr virus infection, can cause symptoms like those of hematologic cancer.
Autoimmune diseases – Some autoimmune diseases, such as lupus, rheumatoid arthritis, and Sjogren’s syndrome, can cause similar symptoms as hematologic cancer.
Other conditions – Other medical conditions such as thyroid disorders, diabetes, and chronic liver or kidney disease can also cause symptoms like hematologic cancer.
Chemotherapy: It is used to destroy cancer cells in the body. It is often the first-line treatment for hematologic cancers. The drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) are commonly used to treat non-Hodgkin lymphoma.
Radiation therapy: Radiation therapy is the use of high-energy radiation to kill cancer cells. This is used to treat some types of lymphoma and leukemia.
Stem cell transplant: It is a procedure in which healthy blood-forming cells are given to replace damaged or destroyed cells. High doses of chemotherapy and/or radiation are used to destroy cancer cells followed by transplanting healthy stem cells to replace the damaged ones.
Targeted therapy: It is a type of cancer treatment that uses drugs to target specific molecules involved in the growth and spread of cancer cells. Targeted therapy drugs such as imatinib, dasatinib, and nilotinib are used to treat chronic myeloid leukemia.
Immunotherapy: It is a type of cancer treatment that helps the immune system to fight against cancer cells. Immunotherapy drugs such as pembrolizumab and nivolumab are used to treat Hodgkin lymphoma and some types of leukemia.
Surgery: Surgery may be performed to remove cancer cells or tissues from the body.
Hematologic cancer, also known as blood cancer or hematopoietic cancer, is a type of cancer that affects the blood, bone marrow, and lymphatic system. This type of cancer occurs when there is an abnormal growth of blood cells in the body, which can lead to the formation of tumors and affect the body’s ability to fight infections.
Hematologic cancers can be broadly categorized into three types: leukemia, lymphoma, and myeloma. The diagnosis and treatment of hematologic cancer depend on the specific type of cancer, stage, and other individual factors. Early diagnosis and treatment are important to improve the prognosis and overall survival of patients with hematologic cancer.
Incidence: Hematologic malignancies have an annual incidence of approximately 75,000 new cases in the United States.
Mortality: Approximately 50,000 people die from hematologic malignancies each year in the United States.
Age: The incidence of hematologic malignancies increases with age. For example, the median age at diagnosis for multiple myeloma is 69 years, while the median age at diagnosis for acute lymphoblastic leukemia is 15 years.
Gender: Hematologic malignancies affect men and women equally, with the exception of some subtypes, such as Hodgkin lymphoma, which has a slightly higher incidence in males.
Race and Ethnicity: Some types of hematologic malignancies, such as multiple myeloma and Hodgkin lymphoma, have a higher incidence among African Americans and Hispanics.
The pathophysiology of hematologic cancers varies depending on the specific type of cancer and can involve mutations in the DNA, uncontrolled cell proliferation, and inhibition of apoptosis.
Mutations in DNA: Hematologic cancers often occur because of genetic mutations in the DNA of blood or bone marrow cells. These mutations can affect the growth and differentiation of blood cells, leading to uncontrolled proliferation and ultimately cancer development.
Uncontrolled cell proliferation: In hematologic cancers, abnormal blood cells proliferate at a rapid rate, leading to an imbalance in the ratio of normal to abnormal cells. This proliferation can lead to the formation of tumors, which can interfere with the normal functioning of the blood and lymphatic system.
Inhibition of apoptosis: Apoptosis, or programmed cell death, is a normal process that helps to remove damaged or abnormal cells from the body. In hematologic cancers, this process is often inhibited, allowing cancerous cells to survive and proliferate.
Genetic mutations: Hematologic cancers are often associated with genetic mutations that occur spontaneously or are inherited. Certain genetic mutations, such as the BCR-ABL gene fusion, are strongly associated with the development of chronic myeloid leukemia (CML).
Environmental factors: Exposure to certain toxins and chemicals, such as benzene and pesticides, has been linked to the development of hematologic cancers.
Viral infections: Certain viral infections, such as Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus type 1 (HTLV-1), have been associated with an increased risk of hematologic cancers.
Immune system disorders: Hematologic cancers may develop in individuals with certain immune system disorders, such as autoimmune diseases and immunodeficiency disorders.
Type of cancer: The prognosis for hematologic cancer varies depending on the specific type of cancer. For example, acute myeloid leukemia (AML) has a generally poorer prognosis than Hodgkin’s lymphoma.
Disease stage: The stage of the cancer at diagnosis is an important factor in predicting prognosis. Hematologic cancers are often classified based on the extent of the disease, ranging from stage I (localized disease) to stage IV (widespread disease).
Molecular characteristics: The presence of certain genetic or molecular abnormalities can impact the prognosis of hematologic cancers. For example, the presence of the Philadelphia chromosome in chronic myelogenous leukemia (CML) is associated with a poorer prognosis.
Patient age and overall health: younger patients with good overall health tend to have a better prognosis than older patients or those with underlying medical conditions.
Response to treatment: Response to initial treatment is a strong predictor of long-term prognosis. Patients who respond well to initial treatment tend to have better outcomes than those who do not.
Presence of comorbidities: The presence of other medical conditions, such as heart disease or diabetes, can impact the prognosis of hematologic cancers.
CLINICAL HISTORY
The clinical history of hematologic cancer can vary depending on the type of cancer and its stage. Generally, patients with hematologic cancer may present with symptoms such as fatigue, weakness, weight loss, night sweats, fever, easy bruising or bleeding, frequent infections, bone pain, and swollen lymph nodes. However, some patients may not experience any symptoms at all, and the cancer may only be detected through routine blood tests or imaging studies.
It is important for individuals with a family history of hematologic cancer or other risk factors to undergo regular check-ups and screenings to detect any abnormalities early on. A thorough medical history, physical examination, and laboratory tests are necessary to confirm the diagnosis of hematologic cancer.
PHYSICAL EXAMINATION
The physical examination for hematologic cancer will involve a thorough assessment of the patient’s overall health and physical condition, with a particular focus on the lymph nodes, spleen, and liver. The examination may include the following:
Lymph node: A thorough examination of the lymph nodes is essential as lymphomas often present with lymphadenopathy. The size, location, and consistency of the lymph nodes are assessed.
Abdominal examination: An enlarged spleen or liver may indicate the presence of a hematologic malignancy. The liver and spleen are palpated to assess their size, consistency, and tenderness.
Skin: The skin may show signs of involvement in some cases of hematologic malignancies such as cutaneous T-cell lymphoma or leukemia cutis. The skin is examined for any lesions, nodules, or rash.
Neurological examination: Patients with hematologic malignancies may present with neurological symptoms such as headaches, visual changes, or peripheral neuropathy. A thorough neurological examination is performed to assess the patient’s mental status, cranial nerves, motor function, and sensory function.
Bone: Patients with hematologic malignancies may present with bone pain or pathologic fractures. A thorough examination of the bones is performed to assess any tenderness or deformities.
Chest: Chest X-ray is usually performed to assess the presence of any mediastinal masses or pulmonary infiltrates.
DIFFERENTIAL DIAGNOSIS
Other types of cancer – non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, leukemia, multiple myeloma, and other types of solid tumors.
Non-cancerous hematologic conditions – Anemia, thrombocytopenia, leukopenia, and other non-malignant hematologic disorders.
Infectious diseases – Some viral and bacterial infections, such as HIV/AIDS, hepatitis B and C, and Epstein-Barr virus infection, can cause symptoms like those of hematologic cancer.
Autoimmune diseases – Some autoimmune diseases, such as lupus, rheumatoid arthritis, and Sjogren’s syndrome, can cause similar symptoms as hematologic cancer.
Other conditions – Other medical conditions such as thyroid disorders, diabetes, and chronic liver or kidney disease can also cause symptoms like hematologic cancer.
Chemotherapy: It is used to destroy cancer cells in the body. It is often the first-line treatment for hematologic cancers. The drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) are commonly used to treat non-Hodgkin lymphoma.
Radiation therapy: Radiation therapy is the use of high-energy radiation to kill cancer cells. This is used to treat some types of lymphoma and leukemia.
Stem cell transplant: It is a procedure in which healthy blood-forming cells are given to replace damaged or destroyed cells. High doses of chemotherapy and/or radiation are used to destroy cancer cells followed by transplanting healthy stem cells to replace the damaged ones.
Targeted therapy: It is a type of cancer treatment that uses drugs to target specific molecules involved in the growth and spread of cancer cells. Targeted therapy drugs such as imatinib, dasatinib, and nilotinib are used to treat chronic myeloid leukemia.
Immunotherapy: It is a type of cancer treatment that helps the immune system to fight against cancer cells. Immunotherapy drugs such as pembrolizumab and nivolumab are used to treat Hodgkin lymphoma and some types of leukemia.
Surgery: Surgery may be performed to remove cancer cells or tissues from the body.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
